Imatinib Induced Bullous Pemphigoid as a Late Toxicity: A possible Need for Post Treatment Follow-Up?
| Main Authors: | Walid Shalata, Itai Levy |
|---|---|
| Format: | Article eJournal |
| Terbitan: |
, 2020
|
| Subjects: | |
| Online Access: |
https://zenodo.org/record/4129793 |
Daftar Isi:
- The novel use of Tyrosine Kinase Inhibitors (TKI ́s) has shown to be a major breakthrough in the treatment of Chronic Myeloid Leukemia (CML). It has opened the doors for TKIs use in a series of neoplasms with success rates previously unheard of. Nevertheless, its use is not free of adverse effects. Skin, gastro-intestinal and central nervous systems arethe most affected, among which autoimmune response can be observed with a higher incidenceintreated populations. Here we report the case of a patient who presented a rare autoimmune disease, bullous pemphigoid, which wasn’t described before as one of the adverse effects (early or late), most probably as a therapy-related adverse effect two years after stopping Imatinib® treatment.